Poster (download)
[pdf-embedder url=”https://bgrssb.icgbio.ru/wp-content/uploads/2020/07/262.pdf”]
Elena Pudova1
1EIMB RAS, pudova_elena@inbox.ru
Prostate cancer is one of the most important socially significant oncological diseases in men. To select an effective approach to therapy, prostate cancer is stratified into appropriate risk groups based on criteria such as TNM status, Gleason score and the level of prostate-specific antigen (PSA). However, to optimize therapy, additional informative markers are necessary, and the aim of this study is to search for these markers at the level of genome methylation. This work included methylation data of prostate cancer from The Cancer Genome Atlas project. The cohort involved patients with high (23 cases) and intermediate (103 cases) risk. As a result, 1,056 differentially methylated CpG sites were found between high and medium risk groups. CpG most interested sites: cg17687367 (chr13: 79936801), cg26874611 (chr5: 168147884), cg06989693 (chr5: 41409252), cg02226810 (chr6: 1605117), cg07736716 (regulation regions: 85): 85 to 91 (85): 85 858: 858: 858: 85: 86: 85: 86: 85: 86: 85: 86: 85: 86: 85: 85.